Planned Parenthood of Northern, Central, and Southern New Jersey, INC.
Planned Parenthood of Northern, Central, and Southern New Jersey, INC. was paid $3.24M by Medicaid between Jan 2018 and Dec 2024, across 29 billing codes. Its largest line is J1050, Injection, medroxyprogesterone acetate, 1 mg — 18% of everything it billed.
TRENTON, NJ 08608
Next to other Non-Pharmacy Dispensing Site providers in New Jersey
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 13,824 | $736K | |
| 2019 | 9,627 | $519K | |
| 2020 | 8,587 | $464K | |
| 2021 | 8,638 | $383K | |
| 2022 | 8,289 | $365K | |
| 2023 | 8,491 | $416K | |
| 2024incomplete | 4,899 | $357K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 18% | 5,471 | 5,468 | $585K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 17% | 6,597 | 6,420 | $562K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 17% | 3,796 | 3,785 | $537K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 14% | 3,035 | 3,017 | $450K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 6.9% | 4,355 | 4,266 | $224K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 5.5% | 2,060 | 2,029 | $179K |
| 81025 | 4.2% | 15,426 | 15,082 | $137K | |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | 2.8% | 4,408 | 4,342 | $90K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 2.7% | 2,868 | 2,807 | $86K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 2.0% | 1,808 | 1,790 | $65K |
| 99201 | 1.5% | 332 | 332 | $49K | |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | 1.2% | 45 | 45 | $40K |
17 more codes
| 87806 | 1.2% | 801 | $37K | |
| J7304 | Contraceptive supply, hormone containing patch, each | 1.1% | 429 | $35K |
| 58300 | 1.0% | 329 | $33K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.0% | 4,709 | $33K |
| 64435 | <1% | 435 | $28K | |
| 76830 | Ultrasound, transvaginal | <1% | 272 | $18K |
| 86703 | <1% | 927 | $17K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 13 | $11K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 38 | $10K |
| 86901 | <1% | 2,374 | $5K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 25 | $3K |
| 85018 | <1% | 998 | $2K | |
| 58301 | <1% | 25 | $2K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 61 | $920.49 |
| J3490 | Unclassified drugs | <1% | 627 | $627.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 27 | $27.00 |
| 86780 | <1% | 64 | $12.75 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.